First FDA-Approved Eye Form of Bevacizumab for Wet AMD
Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration
FDA approval on 24 July 2026 for Lytenava (bevacizumab-vikg) injection — an ophthalmic VEGF inhibitor for intravitreal use — for neovascular…
This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava…